This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
ACIP UpdateAfter the October 2024 ACIP vote, all MenB vaccines now align to the same schedule (2 doses at 0 and 6 months when used as a 2-dose series) for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making.1,2TRUMENBA® has demonstrated coverage against diverse MenB strains by covering both subfamilies A and B of fHbp3-5*

*Based on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.3

ReferencesBased on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.3TRUMENBA is proven to help protect against diverse MenB strains, which is important because you don't know which of the >1800 MenB strains your patients may encounter.3,7*


Learn more about diverse strain protection
Loading Dosing schedule

TRUMENBA offers proven protection with a 2-dose schedule.3

 See the data Loading Diverse strain coverage*

ONLY TRUMENBA covers both subfamilies of fHbp, A & B, that have been found on 99% of MenB disease-causing strains, as well as strains that have caused MenB outbreaks at US colleges.3,8-10‡


 See the science Loading

fHbp=factor H binding protein.

 CDC recommendations

MenB vaccination is part of the CDC
16-year-old vaccination platform.3,6†

Read the recommendations
Loading

CDC=Centers for Disease Control and  Prevention.

 Meningococcal Disease Reminder Program

Learn more about YourNextDose, an adherence program created to ensure your patients complete the meningococcal vaccination series with TRUMENBA following their first dose of PENBRAYA or TRUMENBA.

 Learn moreLoading
Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice


Find out more about TruSupport
LoadingTitle
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 
1-800-666-7248.
ReferencesBased on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.3The Advisory Committee on Immunization Practices (ACIP) recommends 2 doses for persons aged 16 through 23 years who are not at increased risk for meningococcal disease, based on shared clinical decision-making. ACIP recommends 3 doses for persons aged ≥10 years who are at increased risk. Persons at increased risk include those with persistent complement component deficiencies, those with anatomic or functional asplenia, and microbiologists routinely exposed to isolates of Neisseria meningitidis.6Persons at increased risk during an outbreak.9 fHbp=factor H binding protein; MenB=serogroup B meningococcal disease. References:1. Schillie SF. Introduction to MenB-4C (Bexsero) interval and dosing label change. Presented at: Advisory Committee on Immunization Practices; October 24, 2024; Atlanta, GA. Accessed January 13, 2025. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-mening-Schillie-508.pdf 2. Centers for Disease Control and Prevention. Meningococcal vaccine recommendations. Updated October 24, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html 3. TRUMENBA® (Meningococcal Group B Vaccine). Prescribing information. Pfizer; 2024. 4. McDaniel A, Dempsey A, Srivastava A. A physician's guide to the 2-dose schedule of MenB-FHbp vaccine. Hum Vaccin Immunother. 2019;15(11):2729-2737. 5. Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15(2):459-469. 6. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices―United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73:345-350. 7. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379-389. 8. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744. 9. Harris SL, Donald RGK, Hawkins JC, et al. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36(2):216-223. 10. Donald RGK, Hawkins JC, Hao L, et al. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccin Immunother. 2017;13(2):255-265.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-TRU-USA-3203
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.